Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
35.95
-1.06 (-2.88%)
Sep 14, 2026, 3:22 PM EDT - Market open
Nanobiotix Revenue
In the year 2025, Nanobiotix had annual revenue of 32.59M EUR. Nanobiotix had revenue of 5.96M in the half year ending December 31, 2025, a decrease of -81.91%.
Revenue (ttm)
32.59M EUR
Revenue Growth
n/a
P/S Ratio
48.23
Revenue / Employee
325,930 EUR
Employees
100
Market Cap
1.85B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.59M | 39.78M | - |
| Dec 31, 2024 | -7.19M | -43.40M | - |
| Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
| Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
| Dec 31, 2021 | 2.65M | 135.00K | 5.37% |
| Dec 31, 2020 | 2.51M | -29.00K | -1.14% |
| Dec 31, 2019 | 2.54M | -938.00K | -26.96% |
| Dec 31, 2018 | 3.48M | -242.53K | -6.52% |
| Dec 31, 2017 | 3.72M | -1.70M | -31.36% |
| Dec 31, 2016 | 5.42M | 1.41M | 35.03% |
| Dec 31, 2015 | 4.02M | 1.24M | 44.91% |
| Dec 31, 2014 | 2.77M | 2.59M | 1,398.23% |
| Dec 31, 2013 | 184.94K | -785.67K | -80.95% |
| Dec 31, 2012 | 970.61K | -389.71K | -28.65% |
| Dec 31, 2011 | 1.36M | 225.46K | 19.87% |
| Dec 31, 2010 | 1.13M | -1.63M | -59.00% |
| Dec 31, 2009 | 2.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.13B |
| Vericel | 306.30M |
| Vir Biotechnology | 303.23M |
| Xencor | 104.97M |
| Septerna | 98.88M |
| Zymeworks | 37.13M |
| Stoke Therapeutics | 27.59M |
NBTX News
- 10 hours ago - Nanobiotix announces updated safety, efficacy data from JNJ-1900 study - TheFly
- 13 hours ago - NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer - GlobeNewsWire
- 4 days ago - NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 19 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 6 weeks ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 3 months ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 3 months ago - Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029 - Nasdaq
- 3 months ago - Nanobiotix Provides First Quarter 2026 Operational and Financial Update - GlobeNewsWire